Direct-acting antiviral therapy improves kidney survival in hepatitis C virus-associated cryoglobulinaemia: the RENALCRYOGLOBULINEMIC study
Por:
de Jose, A, Carbayo, J, Pocurull, A, Bada-Bosch, T, Corona, C, Shabaka, A, Terrada, N, Valenzuela, L, Huerta, A, Lorente, L, Malek-Marin, T and Goicoechea, M
Publicada:
1 feb 2021
Categoría:
Nephrology
Resumen:
Background. Direct-acting antiviral agents (DAAs) have shown high rates of sustained virological response in chronic hepatitis C virus (HCV) infection. However, the influence of DAAs on the course of kidney involvement in HCV-associated mixed cryoglobulinaemia (HCV-MC) has been little studied. The aim of this study was to analyse the effects of antiviral treatment on kidney prognosis and evolution in patients diagnosed with HCV-MC.
Methods. The RENALCRYOGLOBULINEMIC study is an observational multicentre cohort study of 139 patients with HCV-MC from 14 Spanish centres. Clinical and laboratory parameters were measured before and after antiviral treatment. Primary endpoints were kidney survival and mortality after HCV-MC diagnosis. Secondary endpoints were clinical, immunological and virological responses after antiviral treatment.
Results. Patients were divided into three groups based on the treatment received: treatment with DAAs (n=100) treatment with interferon (IFN) and ribavirin (RBV) (n=24) and no treatment (n=15). Patients were followed up for a median duration of 138 months (interquartile range 70-251. DAA treatment reduced overall mortality {hazard ratio [HR] 0.12 [95% confidence interval (CI) 0.04-0.40]; P<0.001} and improved kidney survival [HR 0.10 (95% CI 0.04-0.33); P<0.001].
Conclusions. Results from the RENALCRYOGLOBULINEMIC study indicated that DAA treatment in patients with HCV-MC improves kidney survival and reduces mortality.
Filiaciones:
de Jose, A:
Univ Hosp Gregorio Maranon, Dept Nephrol, Madrid, Spain
Carbayo, J:
Univ Hosp Gregorio Maranon, Dept Nephrol, Madrid, Spain
Pocurull, A:
Hosp Clin Barcelona, Dept Gastroenterol & Hepatol, Barcelona, Spain
Bada-Bosch, T:
Hosp Univ Doce Octubre, Dept Nephrol, Madrid, Spain
Corona, C:
Hosp Univ Fdn Alcorcon, Dept Nephrol, Madrid, Spain
Shabaka, A:
Hosp Clin Univ San Carlos, Dept Nephrol, Madrid, Spain
Terrada, N:
Hosp Valle De Hebron, Dept Nephrol, Barcelona, Spain
Valenzuela, L:
Hosp Univ Bellvitge, Dept Nephrol, Catalunya, Spain
Huerta, A:
Hosp Univ Puerta Hierro Majadahonda, Dept Nephrol, Madrid, Spain
Lorente, L:
Hosp Navarra, Dept Nephrol, Pamplona, Spain
:
Hosp Sagunto, Dept Nephrol, Sagunto, Spain
Goicoechea, M:
Univ Hosp Gregorio Maranon, Dept Nephrol, Madrid, Spain
Green Published, gold
|